Supernus Pharmaceuticals reported $11.35M in EBIT for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Abbott ABT:US $ 2478M 434M
Aerie Pharmaceuticals AERI:US $ -18137000 15.51M
Aurora Cannabis Inc ACB:CN C$ -86814000 23.72M
Bristol Myers Squibb BMY:US $ 3197M 9M
Canopy Growth Corp WEED:CN -114437000 194.91M
Cara Therapeutics CARA:US $ -4472000 23.44M
Corcept Therapeutics CORT:US $ 31.43M 4.66M
Eisai 4523:JP 7.43B 28.23B
Eli Lilly And LLY:US $ 1650.5M 919.4M
Horizon Pharma HZNP:US 147M 49.44M
JAZZ PHA JAZZ:US 126.35M 38.8M
Lannett LCI:US $ -23942000 3.64M
Marinus Pharmaceuticals MRNS:US -36766000 20.06M
Pacira Pharmaceuticals PCRX:US $ 13.18M 8.55M
Perrigo Ordinary Shares PRGO:US $ 2.6M 20.5M
Pfizer PFE:US $ 12099M 2104M
Revance Therapeutics RVNC:US $ -57842000 4.38M
Supernus Pharmaceuticals SUPN:US $ 11.35M 9.38M
Teva Pharmaceutical Industries TEVA:US 734M 55M
United Therapeutics UTHR:US $ 201.8M 86.2M
Xeris Pharmaceuticals Inc XERS:US $ -18916000 158K